{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-028601","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.396339+00:00","generated_at":"2026-06-24T01:51:18.509969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lyra Therapeutics Q2 net loss $14.5M; cash $120.7M; CMO appointed; Phase 3 enrollment ongoing","bullets":["Net loss $14.5M for Q2 2022 vs $11.0M in Q2 2021; R&D expenses $10.8M.","Cash and equivalents $120.7M as of June 30, 2022; cash runway to mid-2024.","Closed private placement of ~$96.3M net proceeds in April 2022.","Appointed Richard Nieman, MD as Chief Medical Officer.","ENLIGHTEN Phase 3 program enrolling; ENLIGHTEN II first patient expected Q3; enrollment complete mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-028601","json":"https://secwatch.observer/filing/0001564590-22-028601.json","markdown":"https://secwatch.observer/filing/0001564590-22-028601.md","text":"https://secwatch.observer/filing/0001564590-22-028601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000156459022028601/0001564590-22-028601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000156459022028601/lyra-8k_20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:51:18.509969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}